Major changes announced in 2017 Hypertension guidelines by AHA/ACC

The new guideline, updating the currently active JNC 7 guidelines have lowered the definition of Stage 1 HT to 130/80 mm Hg

The American College of Cardiology and The American Heart Association released the updated ACC/AHA Hypertension guidelines yesterday at the AHA 2017 Scientific Sessions and simultaneously published in Journal of American College of Cardiology and Hypertension. As per ACC, this is “the first comprehensive set since 2003”.

The new guidelines have recommended a target BP of130/80 mm Hg during treatment and classified SBP 130-139 mm Hg OR DBP 80-89 mm Hg as Stage 1 Hypertension which was earlier classified as Pre-hypertension.
Key takeaways:
Lifestyle modification recommendations
Patients classified as Stage 1 HT who do not meet the above criteria are only to be recommended Lifestyle modification. Specific recommendations include Emphasising that risk of CVD doubles from Normal BP range to the Stage 1 BP range, Paul K. Whelton, lead author of the guidelines, said: "We want to be straight with people – if you already have a doubling of risk, you need to know about it. It doesn't mean you need medication, but it's a yellow light that you need to be lowering your blood pressure, mainly with non-drug approaches."

The new guidelines lead to a substantial increase in the prevalence of Hypertension with 45.6% of US population now being classified as Hypertensive vs. 31.9% earlier under JNC 7 i.e. 10 cr more Hypertensive patients in the US alone.
About the ACC/AHA guidelines
The new guidelines were developed by ACC and AHA with nine other health professional organizations and were written by a panel of 21 scientists and health experts who reviewed more than 900 published studies. They are the successor to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7), issued in 2003 and overseen by the National Heart, Lung, and Blood Institute (NHLBI). In 2013, the NHLBI asked the AHA and ACC to continue the management of guideline preparation for hypertension and other cardiovascular risk.